source
- Madrigal’s 2024 MASH drug sparks new wave of diagnosis and personalized treatment approachesThe article argues that the field of metabolic dysfunction‑associated steatohepatitis (MASH) is entering a period of rapid innovation, and that the industry must broaden efforts in diagnosis, monit…
- T-Therapeutics secures $133 million Series B to advance bispecific cancer and autoimmune drugsT-Therapeutics, a UK-based biotech focused on T-cell engager technology, announced a $133 million Series B financing. The capital will be used to generate proof-of-concept data for its lead bispec…